文献速递甲状腺与浅表介入US

射频消融与微波消融治疗良性甲状腺结节的疗效与安全性比较:系统综述与荟萃分析

Comparative efficacy and safety of radiofrequency ablation and microwave ablation in benign thyroid nodule treatment: a systematic review and meta-analysis.
PubMed 文献 · Eur Radiol · 2024-07-24

该系统综述与荟萃分析纳入9项研究共1305个射频消融与1276个微波消融治疗的良性甲状腺结节,比较两者疗效与安全性。结果显示1、3、6个月体积缩小率相似,但射频消融12个月体积缩小率(83.3%)显著高于微波消融(76.9%)(p=0.02);并发症率无显著差异;症状与美容评分均显著下降且两组间无显著差异。亚组分析显示操作经验≤10年的研究者中射频消融12个月体积缩小率显著更高,而经验>10年者无显著差异。

要点

  • 射频消融12个月体积缩小率83.3%显著高于微波消融76.9%(p=0.02)。
  • 两种方法并发症率无显著差异,症状与美容评分均显著下降且组间无显著差异。
  • 操作经验≤10年的研究者中射频消融12个月体积缩小率显著高于微波消融。

核心结论

  • 射频消融和微波消融均为治疗良性甲状腺结节有效且安全的方法;射频消融12个月体积缩小率更高,似乎更适合经验较少的研究者。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、EMBASE和COCHRANE数据库至2023年9月25日,纳入9项直接比较射频消融与微波消融治疗病理证实的良性甲状腺结节的研究,共1305个结节行射频消融、1276个结节行微波消融;两位放射科医师独立提取数据并按PRISMA指南进行质量评价。

诊断标准与关键数值

  • 射频消融12个月体积缩小率83.3% vs 微波消融76.9%(p=0.02);1、3、6个月体积缩小率两组相似;并发症率两组无显著差异;症状与美容评分消融后均显著下降且组间无显著差异;亚组分析中操作经验≤10年的研究者射频消融12个月体积缩小率显著高于微波消融,经验>10年者无显著差异。

临床应用与阅片要点

  • 作者认为射频消融和微波消融均为良性甲状腺结节有效且安全的微创治疗选择,射频消融12个月体积缩小率更高,似乎更适合经验较少的研究者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: Ultrasound-guided thermal ablation, including radiofrequency ablation (RFA) and microwave ablation (MWA), has become one of the main options for treating benign thyroid nodules (BTNs). To assess the efficacy of thermal ablation of BTNs, we performed a systematic review and meta-analysis of relevant studies.

MATERIALS AND METHODS: A comprehensive search of MEDLINE, EMBASE, and COCHRANE databases was performed up to September 25, 2023, to identify studies directly comparing RFA and MWA for pathologically proven BTNs and reporting clinical outcomes and complications. Data extraction and quality assessment were independently performed by two radiologists according to PRISMA guidelines. The analysis yielded the serial volume reduction ratios (VRRs) of ablated nodules for up to 12 months, symptom and cosmetic scores, and complications.

RESULTS: This analysis included nine studies with 1305 BTNs treated by RFA and 1276 by MWA. VRRs at 1 month, 3 months, and 6 months were similar between RFA and MWA, but RFA showed a significantly higher VRR (83.3%) than MWA (76.9%) at 12 months (p = 0.02). Complication rates showed no significant difference between the two methods. Symptom and cosmetic scores significantly decreased after ablation, without a significant difference between the methods. Subgroup analysis indicated a significantly higher VRR at 12 months for RFA than for MWA for less experienced investigators (≤ 10 years), but no significant difference for more experienced investigators (> 10 years).

CONCLUSION: RFA and MWA are both effective and safe methods for treating BTNs. RFA showed a higher VRR at 12 months and seems more suitable for less experienced investigators.

CLINICAL RELEVANCE STATEMENT: RFA and MWA are both effective and safe treatments for BTNs, with RFA showing a higher VRR at 12 months. Both methods offer minimally invasive and reliable treatment for thyroid nodules.

KEY POINTS: The most effective thermal ablation technique for BTNs remains undetermined. RFA showed a higher VRR at 12 months than MWA. Both techniques are effective for treating thyroid nodules; RFA offers greater benefits, particularly for less experienced investigators.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Lim H, Cho SJ, Baek JH, et al. Comparative efficacy and safety of radiofrequency ablation and microwave ablation in benign thyroid nodule treatment: a systematic review and meta-analysis. Eur Radiol. 2024. PMID: 39046500. doi:10.1007/s00330-024-10881-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。